|
5.12 Immunothérapies
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5.1 ASCO (général)
|
|
|
ASCO Highlights for Tuesday June 5, 2018 [OBR Blog]
|
|
|
|
|
|
LBA
4008, presented late yesterday, showed proton pump inhibitors with low
dose aspirin for at least 7 years offers modest benefits for people with
Barrett’s esophagus, a risk factor for the development of
adenocarcinoma of the esophagus. And, LBA 3505, presented today showed
no benefit for using hyperthermic intraperitoneal chemotherapy (HIPEC)
during surgery to treat most patients with colorectal cancer with
colorectal peritoneal carcinomatosis, suggesting that many patients can
avoid HIPEC treatment.
|
|
|
|
|
|
|
Doctors Scrutinize Overtreatment, As Cancer Death Rates Decline [NPR]
|
|
|
|
|
|
Cancer
death rates have been falling in recent decades, and that's allowed
researchers to ask another important question: Are some people getting
too much treatment for their cancers? The answer, from the American
Society of Clinical Oncology meeting in Chicago these past few days, is
an emphatic yes.
|
|
|
|
|
|
|
|
ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More [Xconomy]
|
|
|
|
|
|
In
the days before ASCO, Xconomy previewed two major themes: the feverish
and flawed race to develop cancer immunotherapy combinations, and the
progress of “tissue agnostic” cancer drugs, the advanced guard of
precision medicine. Today, we’ll wrap up the ASCO headlines that hit on
those themes and bring you other news from the meeting.
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
|
5.5.16 ASCO (médecine de précision)
|
|
|
|
|
Tailoring cancer treatment to genetic profile extends lives, study finds [The Guardian]
|
|
|
|
|
|
The
study looked at more than 3,700 people with cancer that had proved
difficult to treat and who had already undergone other types of
treatments. Their ages ranged from 16 to 86, with a median of 57. Of
those patients, 1,307 had a known mutation, and 711 received treatment
based on that genetic profile. Those patients were twice as likely to
live three years (15%) versus those who did not receive tailored
treatments (7%).
|
|
|
|
|
|
|
5.5.16.2 ASCO (médecine de précision-sein)
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
5.5.4.5 ASCO (immunothérapies-CAR-T, thérapies cellulaires)
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
Prostate cancer survival odds worse for smokers [Reuters]
|
|
|
|
|
|
It’s
not clear exactly how smoking might lead prostate cancer to develop or
make it more aggressive or more fatal. One possibility is that smoking
causes inflammation, which in turn encourages tumors to grow, or that
nicotine leads malignancies to spread, Shariat said.
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|